NeoStem (NYSE Amex: NBS) is a leader in the development and manufacture of cellular therapies. NeoStem has a strategic combination of revenues, including that which is derived from the contract manufacturing services performed by Progenitor Cell Therapy, LLC, a NeoStem company. NeoStem endeavors to be an integrative force in the cell therapy industry. By vertically integrating the collection, storage and processing of cell units and the development, manufacturing, distribution, and delivery of cell therapy products, they are positioned to take advantage of growth in the cell therapy industry as a whole.
Results from the The PreSERVE-AMI Study, sponsored by Amorcyte, LLC, a NeoStem, Inc. company, indicate that stem cells retrieved pelvic bone marrow restore tissue and improve heart function in heart attack patients. The study evaluated the safety and efficacy of stem cell treatments and focused on patients who had received a stent to open the blocked artery and heart attack injuries caused by a prolonged period of blocked blood supply. The NeoStem company Progenitor Cell Therapy also assisted this study by processing stem cells in preparation for infusion.
Vijaykumar S. Kasi, MD, PhD, principal investigator for the clinical trial at Orlando Regional Medical Center, commented,
"Severe heart failure, often the end result of large or multiple heart attacks, is a major health care challenge, impacting more than five million people in the United States and costing more than $35 billion annually. Stem cell therapy is part of the movement from treatment to cure and has the potential to overcome limitations and expenses of heart transplants and offers hope for patients who are desperately praying for another chance at life."
Read the full article here.